CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 55 target
Drug / intervention
Atezolizumab +2 morebiological
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Clinically suspected SCCHN amenable to surgical resection with therapeutic intent
  • ✓Age ≥18 years
  • ✓Pre-treatment biopsy within 90 days prior to consent or new biopsy during screening
  • ✓Needle biopsy ≥20 Gauge in diameter
Key exclusion· 33
  • ✕Currently participating in or received investigational therapy within 4 weeks
  • ✕Prior anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
  • ✕Systemic steroid therapy or immunosuppressive therapy within 7 days (with exceptions for low-dose/acute use)
  • ✕Active immunodeficiency or history of TB

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03708224
NCT03708224Phase 2RecruitingOn TrackUpdated 17mo ago
Long Recruiting
CompareCT.gov

A Phase II Study of Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Alain Algazi·interventional·Posted Oct 17, 2018·Updated Jan 28, 2025

In Brief

A Phase 2 clinical trial evaluating Atezolizumab, Tocilizumab, and 1 other intervention for Cancer and 3 related conditions. Currently recruiting, targeting 55 participants across 1 site.

Detailed Summary

To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
CountriesUnited States
CollaboratorsGenentech, Inc., American Head and Neck Society

Timeline

Phase 2Recruiting
2019202020212022202320242025202620272028
First PostedOct 17, 2018
Enrollment StartMar 8, 2019
Primary CompletionJun 30, 2028
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 7.7 years agoPrimary completion in 2.0 years

Interventions

Atezolizumabbiological

Given intravenously (IV)

Tocilizumabbiological

Given IV

Tiragolumabbiological

Given IV